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Background: Curcumin (diferuloylmethane) has been associated with the inhibition of angiogenesis, as
well as the prevention of cancers and inﬂammatory processes. The aim of this study was to assess the
efﬁcacy of curcumin in suppressing angiogenesis in the cultured endothelial cells of rat aortic rings.
Methods: Eight-week-old male Wistar rats were randomized into ﬁve groups each with a different
treatment and cell culturing paradigm: controls cultured in the absence of VEGF (vascular endothelial
growth factor) (C), controls cultured in the presence of VEGF (C-V), controls treated with curcumin and
then cultured in media lacking VEGF (C-TC), diabetics cultured in media supplemented with VEGF (D-V)
and diabetics treated with curcumin and then cultured in media supplemented with VEGF (D-V-TC). Each
group consisted of 8 animals. Diabetes was induced in by streptozotocin (STZ; 60 mg/kg body weight, IV).
After 8 weeks, animals were sacriﬁced and their aortas were excised. Ring-shaped explants were
embedded in a 96-well culture plate. Angiogenesis response was measured by counting the number of
primary microtubules in each well.
Results: Optic microscopy revealed that the D-V group had the highest number of microvessels, while
angiogenesis was not observed in the C or C-TC groups. The number of primary microtubules was
signiﬁcantly lower in the D-V-TC group compared to the D-V group (P < 0.05). The D-V-TC group had a
signiﬁcantly higher number of microvessels compared to the C-TC group (P < 0.05).
Conclusion: Curcumin attenuates angiogenesis response in stertozotocin-induced diabetic rats.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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Curcumin (Diferuloylmethane) is the principal component and
active ingredient of turmeric (Curcuma longa), an organic extract of
Curcuma, a rhizomatous herbaceous perennial plant.1 This phyto-
chemical has long been used as a food additive and coloring agent.2
Accumulating evidence suggests that curcumin exhibits various
biofunctions.3 Emerging data have revealed that curcumin pos-
sesses remarkable anti-oxidant, anti-inﬂammatory, anti-
angiogenesis, and anti-carcinogenic properties.4e9
Diabetes mellitus (DM) is a major worldwide concern and its
long-term complications involve various organ systems.10 Hyper-
glycemia plays a deﬁnite role in the clinical manifestation of DM.11
However, excessive angiogenesis, the formation of new blood
vessels from pre-existing vasculatures,12 may also be an importantrsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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betic nephropathy and retinopathy. In vitro angiogenesis assays
contribute to the investigation of both angiogenic inducer and in-
hibitor agents.13 The rat aortic ring model is a well-established
in vitro assay for assessing angiogenesis,13 and many consider it
the best system for simulating physiological conditions found
in vivo.14 Furthermore, it has the advantage of promoting all of the
key steps of the angiogenesis process.15 Vascular endothelial
growth factor (VEGF) is a prominent proangiogenic mediator16 and
therefore can be used as a local inducer of angiogenesis with the
intent of monitoring the potency of inhibitory factors.14
In the study presented here, we explored the angiogenic effects
of curcumin on cultured endothelial cells derived from the strep-
tozotocin (STZ)-induced diabetic rat aortic rings.2. Materials and methods
2.1. Experimental design
Eight-week-old adult male Wistar rats with an average body
weight of 240 ± 20 g (obtained from Pasteur Institute of Iran) were
randomly allotted into ﬁve groups: controls cultured in the absence
of VEGF (C) (Fig. 1), controls cultured in the presence of VEGF (C-V)
(Fig. 2), controls treated with curcumin and then cultured in a
medium lacking VEGF (C-TC) (Fig. 3), diabetics cultured in media
supplemented with VEGF (D-V) (Fig. 4), and diabetics treated with
curcumin and then cultured in media supplemented with VEGF (D-
V-TC) (Fig. 5). Each group contained eight animals. All rats were
provided standard laboratory rodent chow and water ad libitum.
After 2 weeks, the experimental rats (groups D-V and D-V-TC)
received a single intravenous injection of 60 mg/kg of body weight
of STZ,17 whereas the control group received 60 mg/kg of vehicle.
STZ was prepared fresh by dissolving in Na-citrate buffer (Sigma-
Aldrich), pH ¼ 4.5. In order to verify the diabetic condition, 96 h
after the STZ injection, blood glucose levels of the experimental
groups were measured using a portable glucose analyzer, Accu-
check Blood Glucose Meter (Roche Diagnostics, Basel,
Switzerland). Rats with blood glucose levels <15 mmol/L (270 mg/
dl) received another injection of STZ. Following the second injec-
tion, animals with blood glucose levels higher than 15 mmol/L for 2
weeks were considered to be diabetic.
Rats in the curcumin-treated groups (groups C-TC and D-V-TC)
were given a solution of 100 mg/kg of curcumin per day (dissolvedFig. 1. Optic microscopic view of endothelial cells of aortic ring in Group C.in 2 ml DMSO) by intragastric administration. Treatment with
curcumin began 3 days prior to STZ administration and was
continued for 8 weeks.2.2. Animal care
Rats were housed in individual and separate cages in a tem-
perature (23 ± 3 C) and humidity (50 ± 10%) controlled vivarium
with a 12 h light/dark cycle. Body weight was recorded weekly and
food intake was monitored daily. All animals had free access to
water and chow throughout the study. All animal protocols used
were in accordance with the guidelines for care and use of labo-
ratory animals provided by the CPCSEA and was approved by the
animal ethics review committee of our institution.2.3. Rat aortic ring bioassay
At the end of 8 weeks, animals were sacriﬁced by inhalation of
anesthetics under a fume hood. The thoracic aorta was surgically
excised. After deliberate removal of periaortic ﬁbro-adipose tissue,
the aorta was sectioned into 2 mm ring-like segments. The ring-
shaped explants were rinsed in PBS (Sigma-Aldrich, USA;
pH ¼ 7.4) and were embedded in a solution containing 1.6 g/L of
gentamicin dissolved in 50 ml PBS (pH ¼ 7.4). Containers were
maintained at 4 C. The culture mediumwas prepared in a laminar-
ﬂow cabinet by mixing a culture media of Hams F12 (pH ¼ 7.4,
Sigma-Aldrich) and Dulbecco's modiﬁed Eagle's medium (DMEM,
pH ¼ 7.4, Sigma-Aldrich) in a ratio of 50:50. Both media were
ﬁltered through a 0.22 mm hydrophilic cartilage membrane
(Durapore, EMD Millipore). Immediately, after aortic ring embed-
ding, 2.5 mg/L VEGF (Sigma-Aldrich) and 20% fetal calf serum (FCS,
Sigma-Aldrich) were added to the culture medium of groups C-V,
D-V and D-V-TC.
To prepare the culture media, a 96-well culture plate (Greiner
Bio-One, Germany) was covered with ﬁbrin gel and was allowed to
set-up for 1 h at 37 C, 5% CO2. Fibrin gel was obtained by combining
2.5 ml thrombin (Sigma-Aldrich; concentration: 500 ku/L) and
250 ml ﬁbrinogen (Sigma-Aldrich; concentration: 8 g/L), under the
laminar-ﬂow cabinet. Then, the aortic explant was embedded in
each ﬁbrin-coated well and 1 mL of culture media was added to the
medium and was covered with an additional layer of ﬁbrin gel. The
rings were incubated at 37 C, 5% CO2 for 7 days. All assays were
performed in duplicates.Fig. 2. Optic microscopic view of endothelial cells of aortic ring in Group C-V.
Fig. 4. Optic microscopic view of endothelial cells of aortic ring in Group D-V.
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the angiogenesis progress in individual wells. One week after the
incubation, the aortic outgrowth was evaluated by counting new
microvessels every 3 days for 2 weeks, according to the criteria
proposed by Nicosia et al.15 Rings were photographed on day 7. A
hemocytometer device was used to determine the number of new
microtubules. A ManneWhitney U test was employed to assess the
angiogenic response between groups. A two-tailed P-value <0.05
was considered statistically signiﬁcant.
3. Results
Optic microscopy revealed proliferation of endothelial cells into
the surrounding culture media. New endothelial cells had distinct
nuclei, clear borders, and distinguished cellular membranes.
Capillary sprouts, consisting of endothelial cells, were formed and
migrated toward the ﬁbrin gel. Generation of primary microtubules
(tubulogenesis) and extension of new branches into the ﬁbrin gel
was also noted. The gradual extension of microtubules and
convergence of capillary sprouts lead to formation of new vascu-
latures that covered the periaortic space.
To determine whether curcumin would affect neovessel
outgrowth in diabetes mellitus, animals were randomized in four
cohorts of diabetic and non-diabetic, curcumin-treated and non-
curcumin treated. The results showed angiogenesis response in
all groups where VEGF was added to medium, whereas groups C
and C-TC, which did not receive VEGF, failed to generate new blood
vessels.
The angiogenesis response we observed in the two diabetic
cohorts (groups D and D-TC) demonstrated a reduced number of
microvessels in the D-TC group (P < 0.05). The comparison of two
curcumin treated cohorts (groups C-TC and D-V-TC) showed a
higher number of new microvessels in diabetic animals (D-V-TC
group; P < 0.05). Overall, group D-V had the most angiogenesis
response and group C-TC showed the least number of primary tu-
bules (Table 1).
4. Discussion
In this study, we evaluated the angiogenic response of aortic
rings obtained from a rat model of diabetes. The aortic outgrowth
was evaluated by counting the new microvessels every 3 days for 2
weeks, 1 week after the incubation. We showed that the D-V-TCFig. 3. Optic microscopic view of endothelial cells of aortic ring in Group C-TC.group had a lower angiogenic response compared with the D-V
group, a result that illustrates the inhibitory effect of curcumin on
angiogenesis in Wistar rats with diabetes. Curcumin, a natural
derivate of turmeric has been implicated to show potent chemo-
preventive effects in some cancer models.6,7 Previous investigations
indicate that part of the anti-carcinogenic activity of curcumin could
be due to inhibition of angiogenesis. Numerous studies have
inspected the efﬁcacy of curcumin in angiogenesis; however, most
have investigated the inhibitory effect of curcumin on angiogenesis
in cancers and have not explored its role in diabetes.
Angiogenesis is a complex process involving several steps.
Secretion of proangiogenic growth factors initiates the process by
stimulating the endothelial cells. Next, proteinases such as MMP
and UPA will degrade the basal membrane and endothelial cells
proliferate into the surrounding matrix. Endothelial cells migrate,
forming a sprout, and proliferation follows the tip cells, which
move along the growth factor gradient. Primary tubules begin to
form and smoothmuscle cells are recruited, and eventually the new
vessel matures.18,19 To evaluate the angiogenesis response, we
measured the generation of primary microtubules (tubulogenesis)
and extension of new branches into the ﬁbrin gel. The gradual
extension of microtubules and convergence of capillary sprouts
lead to the formation of new vasculatures that covered the peri-
aortic space, indicating angiogenesis.
Angiogenesis is a dynamic process that occurs throughout life,
as many factors affect the demand for oxygen resulting in capil-
laries growing and regressing accordingly. Sprouting angiogenesis
plays a pivotal role in the maintenance of healthy tissues and the
pathogenesis of many chronic diseases. Maintaining control over
abnormal angiogenesis is the goal of many different treatment
paradigms. Decreased angiogenesis could be an effective thera-
peutic intervention in diabetic retinopathy and nephropathy.20,21
Excessive secretion of VEGF is implicated to play an important
role in diabetic kidney diseases and VEGF suppression has been
shown to have protective effects in diabetic nephropathy.20
Several molecular pathways have been proposed in an attempt
to unveil the mechanism of the curcumin effect on the angiogenic
response, and curcumin has been shown to mediate multiple cell
signaling pathways. Many studies have implicated that curcumin
suppresses the transcription and expression of NF-kB, including
cyclin D1, MMP, VEGF, and AP-1.22e24 Curcumin was found to
downregulate MMP-9 and UPA.25 A study exploring the efﬁcacy of
curcumin on tumor angiogenesis reported inhibition of several
Table 1
Mean ± standard deviation of number of new microtubules assessed by Hemocytometer device in Wistar rats of speciﬁed groups. ManneWhitney U test was employed to
assess the angiogenic response between groups.
Wistar rat group Group C Group C-V Group C-TC Group D-V Group D-V-TC
Mean ± Standard deviation 0 ± 0 39.375 ± 3.335* 0 ± 0 68.875 ± 2.850 4 54.625 ± 4.033* 4
*, 4 show a two-tailed P-value of <0.05 between speciﬁed groups.
Fig. 5. Optic microscopic view of endothelial cells of aortic ring in Group D-V-TC.
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neoplastic cells.26 Furthermore, curcumin was demonstrated to
exert an inhibitory effect on protein kinase C and some cell adhe-
sion molecules.27
In the current work, we sought to evaluate the impact curcumin
may have on the angiogenesis process in aortic rings of
sterptozotocin-induced diabetic rats. We found that curcumin effec-
tively prevented the angiogenic response in aortic ringmodels in both
thediabetic andnon-diabetic environment. Several investigatorshave
examined curcumin's inﬂuence in diabetic retinopathy and ne-
phropathy20,28 and found that curcumin demonstrated protective
effects on the kidneyand retina of animalswith diabetesmellitus.29,30
However, no previous studyhas evaluated the effect of curcumin in an
aortic ring assay of diabetic rats. Our results are consistent with
emerging data suggesting that curcumin may function as an anti-
angiogenic agent.9,26,31 Nevertheless, curcumin also appears to be a
stimulator of angiogenesis inwound healing.32
It should be noted that aortic ring model might face some dis-
advantages, while it is a practical in vitro assay of the typical
angiogenesis known to occur in microvessels. Moreover, there is
the possibility of variable angiogenic responses, which we
attempted to overcome by using duplicate assays and measure-
ments. Furthermore, poor bioavailability and fast metabolism could
limit clinical utilization of curcumin.
In conclusion, our data indicate that curcumin suppresses the
angiogenic response in a rat aortic model of diabetes. Curcumin is a
safe and non-toxic phytochemical25,33 and application of curcumin
for the purpose of treatment and prevention of diabetic compli-
cations seems practical. However, further investigation, particularly
in vivo models and clinical trials, are warranted to fully inspect the
angiogenic efﬁcacy of curcumin.Conﬂict of Interest
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